🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Another celebration for our physiologically based pharmacokinetics lead, Shakir Atoyebi. EDCTP emphasise the importance of capacity building and supporting early career researchers. As we near the end of the grant, for the ECRs it is just the start of a career. #AtTheEquatorUG

VirTUAL Consortium EDCTP has brought together clinical and pharmacokinetic approaches to answer questions about dose of ritonavir-boosted atazanavir during TB treatment. We worked with Tabu Capital Ltd to explain our approaches to communities & stakeholders. Global Health EDCTP3

Today is the last official day of VirTUAL Consortium EDCTP. Yesterday evening we discussed data and celebrated the successful capacity building with our scholars all thriving & continuing to work with the group. We will continue this powerful collaboration and network! #AtTheEquatorUG

#AntiviralPK VirTUAL Consortium #PBPK lead Shakir Atoyebi shares model for escalating the dose of ritonavir- boosted atazanavir from once to twice daily when intercurrent rifampicin based TB treatment is required. This escalation seems to overcome DDI #AtTheEquatorUG EDCTP Global Health EDCTP3

Trust between communities and researchers is essential. We are often asked about the number of samples taken during intensive pharmacokinetic sampling visits. We made a suite of short videos to explain this & other elements of the work. EDCTP Global Health EDCTP3 Faculty of Health and Life Sciences #AtTheEquatorUG

VirTUAL Consortium EDCTP explored drug drug interactions. As part of our community engagement we sought ways to explain concepts simply. We worked with Tabu Capital Ltd to produce 1-2 min clips. Here, Scottish dancing meets Pharmacology, in Uganda! #AtTheEquatorUG youtu.be/BdIYj7kvg-w?si…

VirTUAL Consortium EDCTP explored using rifampicin-based TB treatment whilst on atazanavir-based ART. The drug-drug interaction is recognised but we also needed to consider variations between individual patients. This short video explains why #AtTheEquatorUG youtu.be/rWGLsh0YoQE?si…

#AtTheEquatorUG

Through our communications workpackage, we sought to 'demystify' some of the processes involved in pharmacokinetic analysis. These short clips are accessible to communities and healthcare workers. Thanks Tabu Capital Ltd EDCTP Global Health EDCTP3 British Pharmacological Society Health and Life Sciences Public Engagement Infectious Diseases Institute, Makerere University

When new to PK studies, teams often ask why we are so particular about recording exact times of sampling. We made these short videos with Tabu Capital Ltd to explain in simple terms for team members and participants. EDCTP Global Health EDCTP3 British Pharmacological Society #AtTheEquatorUG

We are delighted to publish the #PBPK model for the #DDI between Atazanavir (ATV/r) + Rifampicin in pregnancy. Results suggest similar dose escalation to non-pregnant adults should be sufficient. Congratulations Shakir Atoyebi #AtTheEquatorUG Full paper: ascpt.onlinelibrary.wiley.com/doi/10.1002/ps…

As VirTUAL Consortium ends, we celebrate another key publication showing the relationship between plasma drug concentrations and those at site of action within the cells. EDCTP Shakir Atoyebi Faculty of Health and Life Sciences

Congratulations! Catherine Orrell was an investigator on VirTUAL Consortium particularly with the protocol sampling from complex and understudied groups requiring atazanavir - based antiretroviral therapy. #AtTheEquatorUG SAMRC